课题基金 / 基金详情

Blockade of renal malignant cycle by transcriptional regulation of SLCO transporter

Blockade of renal malignant cycle by transcriptional regulation of SLCO transporter
通过 SLCO 转运蛋白的转录调节阻断肾恶性循环
批准号:
23390033
负责人:
ABE Takaaki
金额:
$11.98万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011-04-01 至 2014-03-31

项目摘要

项目成果

ABE Takaaki的其他基金

相似基金

相关文献

中文摘要
翻译
尿毒症毒素的积聚抑制了各种肾脏转运蛋白的表达,这种抑制可能会进一步降低肾功能,从而导致尿毒症毒素的积聚。吲哚硫酸盐是一种有效的尿毒症毒素,它通过转录因子GATA3直接抑制肾脏特异的有机阴离子转运体SLCO4c1的表达。在这种情况下,大鼠给药后slco4c1的肾脏表达减少,在这种情况下,slco4c1的首选底物之一琥珀酸胍的血浆水平显著增加,而不改变血浆肌酐。此外,在5/6肾切除大鼠中,口服吸附剂AST-120显著降低了血浆硫酸吲哚含量,反之则增加了slco4c1的表达。这些数据表明,清除吲哚硫酸盐并阻断其信号通路可能有助于恢复SLCO4C1介导的尿毒症毒素在CKD中的排泄。
英文摘要
The accumulated uremic toxins inhibit the expression of various renal transporters and this inhibition may further reduce renal function and subsequently cause the accumulation of uremic toxins. Indoxyl sulfate, one of the potent uremic toxins, directly suppresses the renal-specific organic anion transporter SLCO4C1 expression through a transcription factor GATA3.Administration of indoxyl sulfate in rats reduced renal expression of slco4c1 and under this condition, plasma level of guanidinosuccinate, one of the preferable substrates of slco4c1, was significantly increased without changing plasma creatinine. Furthermore, in 5/6 nephrectomized rats, treatment with oral adsorbent AST-120 significantly decreased plasma indoxyl sulfate level and conversely increased the expression of slco4c1. These data suggest that the removal of indoxyl sulfate and blocking its signal pathway may help to restore the SLCO4C1-mediated renal excretion of uremic toxins in CKD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
尿細管排泄機構と尿毒症物質:トランスポーター発現制御による腎不全治療
肾小管排泄机制与尿毒症物质:通过调节转运蛋白表达治疗肾衰竭
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [鈴木健弘, 阿部高明]
通讯作者: 阿部高明
Conformational Change in tRNA is an Early Indicator of Acute Cellular Damage
tRNA 构象变化是急性细胞损伤的早期指标
DOI: --
发表时间: 2014
期刊: J. Am. Soc. Nephrol.
影响因子: --
作者: [大羽輝弥, 澤田英士, 鈴木良明, 山村寿男, 大矢進, 今泉祐治, Mishima E.]
通讯作者: Mishima E.
Identifying the Uremic Compounds Specifically Involved in the Pathophysiology of Hemodialysis Patients by Capillary Electrophoresis-Mass Spectrometry
通过毛细管电泳-质谱法鉴定专门参与血液透析患者病理生理学的尿毒症化合物
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Akiyama Y, Takeuchi Y, Mishima E, Suzuki T, Ito S, Soga T, Abe T]
通讯作者: Abe T
DOI: 10.1007/s10157-011-0467-4
发表时间: 2011-10-01
期刊: CLINICAL AND EXPERIMENTAL NEPHROLOGY
影响因子: 2.3
作者: [Toyohara, Takafumi, Suzuki, Takehiro, Abe, Takaaki]
通讯作者: Abe, Takaaki
共 30 条
    Drug discovery for Diabetic Nephropathy through altering gut microbiota community
    • 批准号:
      20K20604
    • 项目类别:
      Grant-in-Aid for Challenging Research (Pioneering)
    • 资助金额:
      $16.64万
    • 财政年份:
      2020
    • 负责人:
      ABE Takaaki
    • 依托单位:
    Development of novel drugs for CKD
    • 批准号:
      26293031
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.9万
    • 财政年份:
      2014
    • 负责人:
      ABE Takaaki
    • 依托单位:
    Relation between 1-metyl adenosinea and rheumatoid arthritis
    • 批准号:
      26305007
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.4万
    • 财政年份:
      2014
    • 负责人:
      ABE Takaaki
    • 依托单位:
    Indole analog mitochonic acid-5 (MA-5) has novel therapeutic effects on kidney injury
    • 批准号:
      26670070
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.41万
    • 财政年份:
      2014
    • 负责人:
      ABE Takaaki
    • 依托单位:
    海外基金